Chris A. Rallis - 26 Dec 2023 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A. Rallis
Issuer symbol
FENC
Transactions as of
26 Dec 2023
Net transactions value
-$15,151
Form type
4
Filing time
28 Dec 2023, 16:02:09 UTC
Previous filing
20 Nov 2023
Next filing
27 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Sale $15,151 -1,390 -3% $10.90 44,788 26 Dec 2023 Direct F1
transaction FENC Common Shares Options Exercise $4,999 +3,144 +7.3% $1.59* 46,178 26 Dec 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise $4,999 -3,144 -1.7% $1.59* 184,168 26 Dec 2023 Options 3,144 $1.59 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold to satisfy tax obligation on option exercise.
F2 Shares acquired through the exercise of an option contract with strike price of $1.59 and an expiration date of January 24, 2024.
F3 Represents options granted on January 24, 2014, with a strike price of $1.59 and expiration date of January 24, 2024.